Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | HF158K1 |
| Trade Name | |
| Synonyms | HF-158K1|HF 158K1 |
| Drug Descriptions |
HF158K1 is an immunoliposome containing doxorubicin and TL01, an ERBB2 (HER2)-targeted trastuzumab Fab fragment conjugated lipid, which delivers doxirubicin to ERBB2 (HER2)-expressing tumor cells and potentially inhibits DNA replication (NCI Drug Dictionary). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C200828 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| HF158K1 | HF158K1 | 0 | 1 |